Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pistachio and peanut product recalls climb

This article was originally published in The Tan Sheet

Executive Summary

Recalls of pistachio-containing products potentially tainted with salmonella and supplied from Terra Bella, Calif.-based Setton Farms climbed to more than 500 from more than 60 firms as of April 17, according to FDA's Web site (1"The Tan Sheet" April 6, 2009, p. 11). As for the peanut product recalls linked to potential salmonella contamination from supplier the Peanut Corporation of America, recalls reached more than 3,900 products from more than 350 firms, according to FDA (2"The Tan Sheet" Feb. 16, 2009, p. 11)

You may also be interested in...

More Salmonella Problems Point To Holes In Food GMPs

The recall of more than 2 million pounds of pistachios due to contamination could spike complaints about holes in food manufacturing regulations

Ounce Of Prevention Would Have Saved Pounds Of Peanut Pain – Experts

The ripple effect of peanut recalls underscores the importance of steps firms in any industry segment must take to ensure their business partners are not undermining the integrity of the supply chain, experts say

China VBP, Localization And Other Strategies - How Far And Which Way?

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts